Perspective Therapeutics, Inc. (NYSE:CATX) Receives $20.63 Consensus Price Target from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has received a consensus rating of "Buy" from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $20.63.

A number of research analysts have recently commented on the company. UBS Group started coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $20.00 price objective on the stock. Wedbush reissued an "outperform" rating and issued a $20.00 price target on shares of Perspective Therapeutics in a research report on Thursday, October 24th. Bank of America assumed coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They set a "buy" rating and a $24.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Finally, Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating for the company in a research report on Friday, August 16th.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently added to or reduced their stakes in CATX. Sykon Capital LLC raised its stake in shares of Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company's stock valued at $378,000 after buying an additional 1,717 shares in the last quarter. US Bancorp DE increased its stake in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after acquiring an additional 3,866 shares during the period. nVerses Capital LLC bought a new position in Perspective Therapeutics during the third quarter worth about $57,000. Los Angeles Capital Management LLC acquired a new stake in Perspective Therapeutics during the third quarter valued at approximately $153,000. Finally, Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the second quarter valued at approximately $117,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Stock Up 1.2 %

CATX stock traded up $0.15 during trading hours on Tuesday, hitting $12.34. The company's stock had a trading volume of 426,051 shares, compared to its average volume of 681,221. The stock has a 50 day moving average of $13.37. Perspective Therapeutics has a 12 month low of $2.20 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. On average, research analysts expect that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.